

Michelle A Lowes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9219356/publications.pdf>

Version: 2024-02-01

104
papers

13,866
citations

34105

52
h-index

29157

104
g-index

110
all docs

110
docs citations

110
times ranked

12100
citing authors

#	ARTICLE	IF	CITATIONS
1	Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1092-1101.	1.2	77
2	Pipeline Therapeutics. , 2022, , 321-331.		0
3	Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2022, 158, 300.	4.1	33
4	Diagnosing and Managing Hidradenitis Suppurativa in Pediatrics. <i>Pediatric Annals</i> , 2022, 51, e123-e127.	0.8	1
5	Combining medical and surgical management strategies for hidradenitis suppurativa: Need for a treat to target approach. <i>Dermatological Reviews</i> , 2022, 3, 123-125.	0.5	0
6	Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 275-283.	6.7	8
7	Pain management in hidradenitis suppurativa and a proposed treatment algorithm. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 187-199.	1.2	37
8	Diagnosis and management of hidradenitis suppurativa in women. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 54-61.	1.3	10
9	A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance. <i>Journal of Investigative Dermatology</i> , 2021, 141, 316-324.e2.	0.7	44
10	Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils. <i>British Journal of Dermatology</i> , 2021, 184, 1004-1013.	1.5	15
11	A Comparison of International Management Guidelines for Hidradenitis Suppurativa. <i>Dermatology</i> , 2021, 237, 81-96.	2.1	68
12	Physician perspectives on complementary and alternative medicine in hidradenitis suppurativa. <i>Dermatologic Therapy</i> , 2021, 34, e14851.	1.7	3
13	Elevated Plasma Complement Proteins in Palmoplantar Pustulosis: A Potential Therapeutic Target. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 449-450.	1.2	1
14	Expert Knowledge, Attitudes, and Practices in Management of Hidradenitis Suppurativa Pain. <i>JAMA Dermatology</i> , 2021, 157, 464.	4.1	7
15	Provider perspectives on the management of hidradenitis suppurativa in pregnancy – A survey study. <i>International Journal of Women's Dermatology</i> , 2021, 7, 346-348.	2.0	3
16	Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor- α Inhibitors?. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 139-147.	6.7	6
17	Hidradenitis Suppurativa Specialty Clinics in the USA. <i>Skin Appendage Disorders</i> , 2021, 7, 359-362.	1.0	2
18	Clinical considerations in the management of hidradenitis suppurativa in women. <i>International Journal of Women's Dermatology</i> , 2021, 7, 664-671.	2.0	7

#	ARTICLE	IF	CITATIONS
19	Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 45-53.	1.2	13
20	Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 366-376.	1.2	165
21	Role of the Complement Pathway in Inflammatory Skin Diseases: A Focus on Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2020, 140, 531-536.e1.	0.7	28
22	What causes hidradenitis suppurativa ?â€”15 years after. <i>Experimental Dermatology</i> , 2020, 29, 1154-1170.	2.9	90
23	Creation of a Registry to Address Knowledge Gaps in Hidradenitis Suppurativa and Pregnancyâ€”Reply. <i>JAMA Dermatology</i> , 2020, 156, 354.	4.1	1
24	Special considerations for women with hidradenitis suppurativa. <i>International Journal of Women's Dermatology</i> , 2020, 6, 85-88.	2.0	17
25	Wound Healing in Hidradenitis Suppurativa. <i>Updates in Clinical Dermatology</i> , 2020, , 177-186.	0.1	1
26	CARD14-Mediated Psoriasis and Pityriasis Rubra Piliaris (PRP). , 2020, , 92-95.		0
27	Hemoglobin as an indicator of disease activity in severe hidradenitis suppurativa. <i>International Journal of Dermatology</i> , 2019, 58, 1090-1091.	1.0	3
28	Hemoglobin Levels and Serum C-Reactive Protein in Patients With Moderate to Severe Hidradenitis Suppurativa. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 501-506.	1.2	7
29	Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies. <i>British Journal of Dermatology</i> , 2019, 181, 1339-1341.	1.5	28
30	Distribution of Self-reported Hidradenitis Suppurativa Age at Onset. <i>JAMA Dermatology</i> , 2019, 155, 971.	4.1	40
31	North American clinical management guidelines for hidradenitis suppurativa: AÂ”publication from the United States and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 91-101.	1.2	206
32	African American Patients With Hidradenitis Suppurativa Have Significant Health Care Disparities: A Retrospective Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 334-336.	1.2	18
33	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 76-90.	1.2	218
34	Are Bacteria Infectious Pathogens in Hidradenitis Suppurativa? Debate at the Symposium for Hidradenitis Suppurativa Advances Meeting, November 2017. <i>Journal of Investigative Dermatology</i> , 2019, 139, 13-16.	0.7	26
35	Quality of life and sexual health in patients with hidradenitis suppurativa. <i>International Journal of Women's Dermatology</i> , 2018, 4, 74-79.	2.0	52
36	Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment. <i>Journal of Investigative Dermatology</i> , 2018, 138, 273-281.	0.7	40

#	ARTICLE	IF	CITATIONS
37	Polyclonal hyperglobulinaemia and elevated acute-phase reactants in hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2018, 178, e134-e135.	1.5	11
38	Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature. <i>PLoS ONE</i> , 2018, 13, e0203672.	2.5	71
39	Inflammation: A Contributor to Depressive Comorbidity in Inflammatory Skin Disease. <i>Skin Pharmacology and Physiology</i> , 2018, 31, 246-251.	2.5	56
40	CARD14-Mediated Psoriasis and Pityriasis Rubra Pilaris (PRP)., 2018, , 1-4.		0
41	A randomized clinical trial in vitamin D-deficient adults comparing replenishment with oral vitamin D3 with narrow-band UV type B light: effects on cholesterol and the transcriptional profiles of skin and blood. <i>American Journal of Clinical Nutrition</i> , 2017, 105, 1230-1238.	4.7	27
42	Pain, Psychological Comorbidities, Disability, and Impaired Quality of Life in Hidradenitis Suppurativa. <i>Current Pain and Headache Reports</i> , 2017, 21, 49.	2.9	77
43	IFN γ -Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. <i>Cell</i> , 2017, 170, 127-141.e15.	28.9	140
44	Pathophysiology of hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2017, 36, 47-54.	1.6	93
45	Major gaps in understanding and treatment of hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2017, 36, 86-92.	1.6	22
46	Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions—Lessons Learned From Focus Groups. <i>JAMA Dermatology</i> , 2016, 152, 720.	4.1	1
47	The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2173-2182.	0.7	47
48	Isotretinoin treatment in a patient with known peanut allergy and positive IgE test results for soybean. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 558-559.	1.0	5
49	The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1830-1840.	2.9	108
50	Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets. <i>Journal of Investigative Dermatology</i> , 2016, 136, 161-172.	0.7	51
51	Humanized anti-IFN γ (HuZAF) in the treatment of psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 553-556.e3.	2.9	93
52	Deep Sequencing of the T-cell Receptor Repertoire Demonstrates Polyclonal T-cell Infiltrates in Psoriasis. <i>Frontiers in Immunology</i> , 2015, 4, 460.	1.6	40
53	Immunology of Psoriasis. <i>Annual Review of Immunology</i> , 2014, 32, 227-255.	21.8	1,242
54	CARD14 Expression in Dermal Endothelial Cells in Psoriasis. <i>PLoS ONE</i> , 2014, 9, e111255.	2.5	52

#	ARTICLE	IF	CITATIONS
55	IL-17 and TNF Synergistically Modulate Cytokine Expression while Suppressing Melanogenesis: Potential Relevance to Psoriasis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2741-2752.	0.7	156
56	The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. <i>Trends in Immunology</i> , 2013, 34, 174-181.	6.8	399
57	Gene Profiling of Narrowband UVB-Induced Skin Injury Defines Cellular and Molecular Innate Immune Responses. <i>Journal of Investigative Dermatology</i> , 2013, 133, 692-701.	0.7	44
58	TREM-1 as a Potential Therapeutic Target in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1742-1751.	0.7	46
59	A Single Intradermal Injection of IFN- γ Induces an Inflammatory State in Both Non-Lesional Psoriatic and Healthy Skin. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1177-1187.	0.7	94
60	Putting together the psoriasis puzzle: an update on developing targeted therapies. <i>DMM Disease Models and Mechanisms</i> , 2012, 5, 423-433.	2.4	111
61	Post-Therapeutic Relapse of Psoriasis after CD11a Blockade Is Associated with T Cells and Inflammatory Myeloid DCs. <i>PLoS ONE</i> , 2012, 7, e30308.	2.5	29
62	Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the "Core" Pathogenesis of Disease. <i>PLoS ONE</i> , 2012, 7, e44274.	2.5	149
63	PSORS2 Is Due to Mutations in CARD14. <i>American Journal of Human Genetics</i> , 2012, 90, 784-795.	6.2	365
64	Rare and Common Variants in CARD14, Encoding an Epidermal Regulator of NF-kappaB, in Psoriasis. <i>American Journal of Human Genetics</i> , 2012, 90, 796-808.	6.2	306
65	Homeostatic Tissue Responses in Skin Biopsies from NOMID Patients with Constitutive Overproduction of IL-1 β . <i>PLoS ONE</i> , 2012, 7, e49408.	2.5	36
66	Resolved Psoriasis Lesions Retain Expression of a Subset of Disease-Related Genes. <i>Journal of Investigative Dermatology</i> , 2011, 131, 391-400.	0.7	164
67	Tumor-Associated Macrophages in the Cutaneous SCC Microenvironment Are Heterogeneously Activated. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1322-1330.	0.7	160
68	Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1322-30.	0.7	81
69	Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept. <i>BMC Dermatology</i> , 2010, 10, 1.	2.1	42
70	A Subpopulation of CD163-Positive Macrophages Is Classically Activated in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2412-2422.	0.7	249
71	Evaluation of the Psoriasis Transcriptome across Different Studies by Gene Set Enrichment Analysis (GSEA). <i>PLoS ONE</i> , 2010, 5, e10247.	2.5	161
72	Effective Narrow-Band UVB Radiation Therapy Suppresses the IL-23/IL-17 Axis in Normalized Psoriasis Plaques. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2654-2663.	0.7	136

#	ARTICLE	IF	CITATIONS
73	Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 1261-1268.e9.	2.9	95
74	Cytokine-Producing Dendritic Cells in the Pathogenesis of Inflammatory Skin Diseases. <i>Journal of Clinical Immunology</i> , 2009, 29, 247-256.	3.8	90
75	Psoriasis Is Characterized by Accumulation of Immunostimulatory and Th1/Th17 Cell-Polarizing Myeloid Dendritic Cells. <i>Journal of Investigative Dermatology</i> , 2009, 129, 79-88.	0.7	374
76	Resident and Inflammatory Dendritic Cells in Human Skin. <i>Journal of Investigative Dermatology</i> , 2009, 129, 302-308.	0.7	262
77	Myeloid Dendritic Cells from Human Cutaneous Squamous Cell Carcinoma Are Poor Stimulators of T-Cell Proliferation. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2451-2462.	0.7	79
78	Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 1022-1030.e395.	2.9	273
79	Lack of Functionally Active Melan-A26-35-Specific T Cells in the Blood of HLA-A2+ Vitiligo Patients. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1977-1980.	0.7	6
80	Cellular Genomic Maps Help Dissect Pathology in Human Skin Disease. <i>Journal of Investigative Dermatology</i> , 2008, 128, 606-615.	0.7	31
81	Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1207-1211.	0.7	910
82	Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. <i>British Journal of Dermatology</i> , 2008, 159, ???-???	1.5	666
83	Blockade of CD11a by Efalizumab in Psoriasis Patients Induces a Unique State of T-Cell Hyporesponsiveness. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1182-1191.	0.7	54
84	Identification of Cellular Pathways of Type 1, Th17 T Cells, and TNF- and Inducible Nitric Oxide Synthase-Producing Dendritic Cells in Autoimmune Inflammation through Pharmacogenomic Study of Cyclosporine A in Psoriasis. <i>Journal of Immunology</i> , 2008, 180, 1913-1920.	0.8	165
85	Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis. <i>Journal of Immunology</i> , 2008, 181, 7420-7427.	0.8	300
86	Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. <i>Journal of Experimental Medicine</i> , 2007, 204, 3183-3194.	8.5	604
87	Novel Insight into the Agonistic Mechanism of Alefacept In Vivo: Differentially Expressed Genes May Serve as Biomarkers of Response in Psoriasis Patients. <i>Journal of Immunology</i> , 2007, 178, 7442-7449.	0.8	54
88	Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. <i>Journal of Translational Medicine</i> , 2007, 5, 27.	4.4	60
89	Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 1210-1217.	2.9	220
90	Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. <i>BMC Dermatology</i> , 2007, 7, 2.	2.1	20

#	ARTICLE	IF	CITATIONS
91	Human Basal Cell Carcinoma Is Associated with Foxp3+ T cells in a Th2 Dominant Microenvironment. <i>Journal of Investigative Dermatology</i> , 2007, 127, 2391-2398.	0.7	109
92	Pathogenesis and therapy of psoriasis. <i>Nature</i> , 2007, 445, 866-873.	27.8	1,543
93	Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIa+ macrophages. <i>Journal of Clinical Investigation</i> , 2007, 117, 2517-2525.	8.2	262
94	Prominent Production of IL-20 by CD68+/CD11c+ Myeloid-Derived Cells in Psoriasis: Gene Regulation and Cellular Effects. <i>Journal of Investigative Dermatology</i> , 2006, 126, 1590-1599.	0.7	88
95	Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. <i>BMC Dermatology</i> , 2005, 5, 9.	2.1	26
96	Increase in TNF- α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 19057-19062.	7.1	426
97	TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques. <i>Journal of Immunology</i> , 2005, 175, 2721-2729.	0.8	348
98	Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2075-2080.	7.1	203
99	Current concepts in the immunopathogenesis of psoriasis. <i>Dermatologic Clinics</i> , 2004, 22, 349-369.	1.7	42
100	Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. <i>Clinical Immunology</i> , 2004, 113, 38-46.	3.2	74
101	Cytokine profiles in spontaneously regressing basal cell carcinomas. <i>British Journal of Dermatology</i> , 2000, 143, 91-98.	1.5	84
102	Benign melanocytic proliferative nodule within a congenital naevus. <i>Australasian Journal of Dermatology</i> , 2000, 41, 109-111.	0.7	33
103	Transient reactive papulotranslucent acrokeratoderma associated with cystic fibrosis. <i>Australasian Journal of Dermatology</i> , 2000, 41, 172-174.	0.7	87
104	T Helper 1 Cytokine mRNA Is Increased in Spontaneously Regressing Primary Melanomas. <i>Journal of Investigative Dermatology</i> , 1997, 108, 914-919.	0.7	104